课题基金 / 基金详情

Genetic Variation and Evolution of Artemisinin Resistance

Genetic Variation and Evolution of Artemisinin Resistance
青蒿素耐药性的遗传变异和进化
批准号:
9026563
负责人:
Daniel L HARTL
金额:
$65.31万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-04-05 至 2018-03-31

项目摘要

项目成果

Daniel L HARTL的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供): 青蒿素抗性的遗传变异和进化疟疾是世界上最大的杀手之一。《2010年世界疟疾报告》估计,每年有近2.25亿人死于这种疾病,其中约100万人将死于疟疾。在缺乏有效的疟疾疫苗的情况下,化疗仍然是治疗和预防该疾病的主要手段。恶性疟原虫是最危险的疟疾类型,它的遗传变异是其传播成功的基础,并阻碍了控制疾病的努力。对抗疟疾药物,如抗疟疾药物,如抗叶酸和氯喹的抗药性已经从亚洲蔓延到整个非洲,对二线和三线药物的抗药性现在很常见。利用群体遗传学和基因组学的工具,青蒿素抗性的遗传变异和进化项目将通过确认青蒿素耐药表型,确定与青蒿素耐药有关的基因,验证参与青蒿素耐药的候选基因,从而扩大我们对疟疾遗传变异和疟疾寄生虫微生物耐药性的基本认识。由于出现抗药性的速度可能超过有效的新抗疟疾药物的开发速度,因此开发针对新出现的抗药性的早期预警系统是战胜疟疾的一个重要组成部分。
英文摘要
DESCRIPTION (provided by applicant): Genetic Variation and Evolution of Artemisinin Resistance Malaria is one of the biggest killers in the world. The 2010 World Malaria Report estimates that almost 225 million people each year become acutely ill from the disease-and approximately one million will die from malaria. In the absence of an effective malaria vaccine, chemotherapy remains the mainstay for treatment and prevention of the disease. Genetic variability of the most dangerous type of malaria, Plasmodium falciparum, underlies its transmission success and impedes efforts to control disease. Drug resistance to antimalarial drugs such as antifolates and chloroquine has spread from Asia throughout Africa and resistance to second and third line drugs is now commonplace. Using the tools of population genetics and genomics, the "Genetic Variation and Evolution of Artemisinin Resistance" project will expand our fundamental understanding of both the genetic variation of malaria and microbial drug resistance among malaria parasites by confirming artemisinin resistance phenotypes, identify the gene (or genes) involved in artemisinin drug resistance, and validate the candidate gene (or genes) involved in artemisinin resistance. Because the emergence of drug resistance threatens to outpace the development of effective new antimalarial drugs, the development of an early warning system for emerging resistance is an essential component to defeating malaria.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Evolutionary medicine in the development of antimalaria drugs
  • 批准号:
    8691243
  • 项目类别:
  • 资助金额:
    $33.8万
  • 财政年份:
    2014
  • 负责人:
    Daniel L HARTL
  • 依托单位:
Evolutionary medicine in the development of antimalaria drugs
  • 批准号:
    8820233
  • 项目类别:
  • 资助金额:
    $33.8万
  • 财政年份:
    2014
  • 负责人:
    Daniel L HARTL
  • 依托单位:
Evolutionary medicine in the development of antimalaria drugs
  • 批准号:
    9198129
  • 项目类别:
  • 资助金额:
    $2.28万
  • 财政年份:
    2014
  • 负责人:
    Daniel L HARTL
  • 依托单位:
Genetic Variation and Evolution of Artemisinin Resistance
  • 批准号:
    8822805
  • 项目类别:
  • 资助金额:
    $66.86万
  • 财政年份:
    2013
  • 负责人:
    Daniel L HARTL
  • 依托单位:
海外基金